RBC Capital Reiterates Sector Perform on Pacira BioSciences, Maintains $18 Price Target

Pacira Pharmaceuticals, Inc. -2.21% Post

Pacira Pharmaceuticals, Inc.

PCRX

26.53

26.53

-2.21%

0.00% Post

RBC Capital analyst Gregory Renza reiterates Pacira BioSciences (NASDAQ: PCRX) with a Sector Perform and maintains $18 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via